Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection
Protease Inhibitors (PIs)
(Last updated:2/12/2014; last reviewed:2/12/2014)
Fosamprenavir (FPV, Lexiva)
Fosamprenavir (FPV, Lexiva)
For additional information see Drugs@FDA: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
Tablets: 700 mg
Oral suspension: 50 mg/mL
Pediatric Dose (Aged >6 Months to 18 Years):
- Unboosted fosamprenavir (without ritonavir) is Food and Drug Administration (FDA)-approved for antiretroviral (ARV)-naive children aged 2 to 5 years, but not recommended by The Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children (the Panel) because of low exposures (see text below).
- Boosted fosamprenavir (with ritonavir) is FDA-approved for ARV-naive infants at least 4 weeks of age and for treatment-experienced infants at least 6 months of age; however, the Panel does not recommend use in infants younger than 6 months because of similarly low exposures (see text below). If used in infants as young as 4 weeks, it should only be administered to infants born at 38 weeks gestation or greater.
Aged ≥6 Months to 18 Years:
Twice-Daily Dosage Regimens by Weight for Pediatric Patients at Least 6 Months of Age Using Lexiva Oral Suspension with Ritonavir
* Not to exceed the adult dose of fosamprenavir 700 mg plus ritonavir 100 mg twice daily.
Fosamprenavir Plus Ritonavir
Both twice daily* with food
||fosamprenavir 45 mg/kg plus ritonavir 7 mg/kg
|11 kg to <15 kg
||fosamprenavir 30 mg/kg plus ritonavir 3 mg/kg
|15 kg to <20 kg
||fosamprenavir 23 mg/kg plus ritonavir 3 mg/kg
||fosamprenavir 18 mg/kg plus ritonavir 3 mg/kg
Note: When administered with ritonavir, the adult regimen of 700 mg fosamprenavir tablets plus 100 mg ritonavir, both given twice daily, can be used in patients weighing ≥39 kg. Ritonavir pills can be used in patients weighing ≥33 kg.
Once-daily dosing is not recommended for any pediatric patient.
Adolescent/Adult (Aged >18 Years) Dose:
- Dosing regimen depends on whether the patient is ARV naive or ARV experienced.
Boosted with Ritonavir, Twice-Daily Regimen:
Boosted with Ritonavir, Once-Daily Regimen:
- Fosamprenavir 700 mg plus ritonavir 100 mg, both twice daily.
Protease Inhibitor (PI)-Experienced Patients:
- Fosamprenavir 1400 mg plus ritonavir 100–200 mg, both once daily.
Fosamprenavir in Combination with Efavirenz (Adult):
- Fosamprenavir 700 mg plus ritonavir 100 mg, both twice daily.
- Note: Once-daily administration of fosamprenavir plus ritonavir is not recommended.
- Only fosamprenavir boosted with ritonavir should be used in combination with efavirenz.
PI-Naive Patients Only, Once-Daily Regimen:
- Fosamprenavir 700 mg plus ritonavir 100 mg, both twice daily plus efavirenz 600 mg once daily.
- Fosamprenavir 1400 mg plus ritonavir 300 mg plus efavirenz 600 mg, all once daily.
Selected Adverse Events
- Diarrhea, nausea, vomiting
- Skin rash (fosamprenavir has a sulfonamide moiety. Stevens-Johnson syndrome and erythema multiforme have been reported.)
- Hyperlipidemia, hyperglycemia
- Transaminase elevation
- Fat maldistribution
- Possible increased bleeding episodes in patients with hemophilia
- Fosamprenavir tablets with ritonavir should be taken with food. Pediatric patients should take the suspension with food.
- Patients taking antacids or buffered formulations of didanosine should take fosamprenavir at least 1 hour before or after antacid or didanosine use.
- Fosamprenavir contains a sulfonamide moiety. The potential for cross sensitivity between fosamprenavir and other drugs in the sulfonamide class is unknown. Fosamprenavir should be used with caution in patients with sulfonamide allergy.
- Shake oral suspension well before use. Refrigeration is not required.
- The prodrug fosamprenavir is rapidly and almost completely hydrolyzed to amprenavir by cellular phosphatases in the gut as it is absorbed.
- Amprenavir is a cytochrome P450 3A4 (CYP3A4) inhibitor, inducer, and substrate.
- Dosing in patients with hepatic impairment: Dosage adjustment is recommended. Please refer to the package insert.
Drug Interactions (See also the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents)
- Fosamprenavir has the potential for multiple drug interactions.
- Before administration, a patient’s medication profile should be carefully reviewed for potential drug interactions with fosamprenavir.
- More common: Vomiting, nausea, diarrhea, perioral paresthesia, headache, rash, and lipid abnormalities.
- Less common (more severe): Life-threatening rash, including Stevens-Johnson syndrome, in <1% of patients. Fat maldistribution, neutropenia, and elevated serum creatinine kinase levels.
- Rare: New-onset diabetes mellitus, hyperglycemia, ketoacidosis, exacerbation of pre-existing diabetes mellitus, spontaneous bleeding in hemophiliacs, hemolytic anemia, elevation in serum transaminases, angioedema, and nephrolithiasis.
- Pediatric specific: Vomiting was more frequent in children than in adults in clinical trials of fosamprenavir with ritonavir, (20%–36% vs. 10%, respectively) and in trials of fosamprenavir without ritonavir (60% vs. 16%, respectively). Neutropenia was also more common in children across all the trials (15% vs. 3%, respectively).1
The International AIDS Society-USA (IAS-USA) maintains a list of updated resistance mutations (see http://www.iasusa.org/resistance_mutations/index.html
) and the Stanford University HIV Drug Resistance Database offers a discussion of each mutation (see http://hivdb.stanford.edu/pages/GRIP/APV_fosamprenavir.html
Fosamprenavir is Food and Drug Administration (FDA)-approved for use in children as young as age 4 weeks, but The Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children (the Panel) recommends use only in children aged 6 months or older. While unboosted fosamprenavir has been approved by the FDA for antiretroviral-naive children aged 2 to 5 years, the Panel does not recommend unboosted fosamprenavir for this—or any other—age group because of low exposures and because unboosted fosamprenavir may select for mutations associated with resistance to darunavir.2
Efficacy and Pharmacokinetics
Dosing recommendations for fosamprenavir are based on 3 pediatric studies that enrolled over 200 children aged 4 weeks to 18 years. In 2 open-label trials in both treatment-experienced and treatment-naive children from ages 2 to 18 years,3,4
fosamprenavir was well-tolerated and effective in suppressing viral load and increasing CD4 T lymphocyte count. However, data were insufficient to support a once-daily dosing regimen of ritonavir-boosted fosamprenavir in children; therefore, once-daily dosing is not recommended for pediatric patients.
Pharmacokinetics in Infants
In a study of infants, higher doses of both fosamprenavir and ritonavir were used in treatment-naive infants as young as age 4 weeks and in treatment-experienced infants as young as age 6 months.1
Exposures in those younger than age 6 months were much lower than those achieved in older children and adults and comparable to those seen with unboosted fosamprenavir. Given these low exposures, limited data, large volumes, unpleasant taste, and the availability of alternatives for infants and young children, the Panel does not recommend fosamprenavir use in infants younger than 6 months.
Except Where Noted
|Infants <6 months
45 mg fosamprenavir/10 mg ritonavir per kg twice daily
|Children aged 2 to <6 years
30 mg fosamprenavir per kg twice daily (no ritonavir)
|Children weighing <11 kg
45 mg fosamprenavir/7 mg ritonavir per kg twice daily
|Children weighing 15 to <20 kg
23 mg fosamprenavir/3 mg ritonavir per kg twice daily
|Children weighing ≥20 kg
18 mg fosamprenavir/3 mg ritonavir per kg twice daily (maximum 700/100 mg )
1400 mg fosamprenavir twice daily (no ritonavir)
1400 mg fosamprenavir/100–200 mg ritonavir once daily
||700 mg fosamprenavir/100 mg ritonavir twice daily
- Food and Drug Administration. Lexiva FDA Label. 2013. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021548s031,022116s015lbl.pdf.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2012. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
- Chadwick E, Borkowsky W, Fortuny C, et al. Safety and antiviral activity of fosamprenavir/ritonavir once daily regimens in HIV-infected pediatric subjects ages 2 to 18 years (48-week interim data, study apv20003). Paper presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA.
- Voronin E, Fortuny C, Perez-Tamarit D, et al. Pharmacokinetics, safety and antiviral activity of fosamprenavir-containing regimens in HIV-positive 2 to 18 year-old children (48-week data, Study APV29005, a prospective, open-label, multi-centre, 48-week cohort study). Abstract no. MOPE049. Paper presented at: 19th International AIDS Conference; 2012; Washington, DC.